{"id":240951,"date":"2026-07-15T20:10:20","date_gmt":"2026-07-16T01:10:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/07\/new-tool-makes-immune-therapy-more-effective-in-prostate-cancer"},"modified":"2026-07-15T20:10:20","modified_gmt":"2026-07-16T01:10:20","slug":"new-tool-makes-immune-therapy-more-effective-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/07\/new-tool-makes-immune-therapy-more-effective-in-prostate-cancer","title":{"rendered":"New tool makes immune therapy more effective in prostate cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-tool-makes-immune-therapy-more-effective-in-prostate-cancer.jpg\"><\/a><\/p>\n<p>Prostate cancer is often resistant to immunotherapy, which harnesses a person\u2019s immune system to recognize and destroy tumors. But a new technology that targets RNA in cancer cells gave immunotherapy new life, improving its ability to unleash cancer-killing cells in laboratory studies.<\/p>\n<p>Most prostate tumors are dubbed \u201cimmune cold\u201d because they don\u2019t attract T cells (a type of immune cell) to the tumor. Using a CRISPR-based tool, researchers altered RNA to make the cancer cells more like magnets for T cells, allowing them to draw in and use the antitumor cells to destroy the cancer.<\/p>\n<p>Published in <i>Nature Biomedical Engineering<\/i>, the <a href=\"https:\/\/www.nature.com\/articles\/s41551-026-01720-9\" target=\"_blank\">study<\/a> found the technology made prostate tumors more responsive to immune checkpoint therapy in mice, increasing the number of immune cells that infiltrated the tumor and subsequently destroyed cancerous cells.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prostate cancer is often resistant to immunotherapy, which harnesses a person\u2019s immune system to recognize and destroy tumors. But a new technology that targets RNA in cancer cells gave immunotherapy new life, improving its ability to unleash cancer-killing cells in laboratory studies. Most prostate tumors are dubbed \u201cimmune cold\u201d because they don\u2019t attract T cells [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-240951","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=240951"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240951\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=240951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=240951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=240951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}